ZYBERNO
Stock Report
Updated Sep 1, 2026

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Healthcare • OTC

$1.07

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-974.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.07
Market Cap:$11.75M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$13.10M

Price Action & Momentum (3)

Momentum Percentile:28 / 100
% of 52-Week High:63.0%
B. Profitability Assessment

Return Metrics (4)

ROA:-1,066.9%
Reinvestment Rate:2.7%
Fundamental Growth Rate (g):-26.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$86.87
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:1.8%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.03x
Quick Ratio:0.03x
Cash Ratio:0.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-12,069,000.00
Cash And Cash Equivalents:22,000.00
Long Term Debt:$113.00K
Net Debt:$1.35M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$9.95M

Bottom Line Performance (3)

-$10.52M
Income Before Tax:-$10.31M
Ebitda Ttm:-9,771,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:3,476,000.00
Sga Expense:6,474,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$788.00K
Current Assets:$316.00K
Ppe Net:152,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:12,385,000.00
Current Liabilities:12,385,000.00
Long Term Debt:$113.00K
Short Term Debt:$1.26M

Equity & Capital (3)

Equity:-$11.60M
Retained Earnings:-$242.93M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:7,488,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:133,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$4.06M$0.00

Investment Activities (1)

Investing Cash Flow:-$1.99M

Financing Activities (3)

Financing Cash Flow:$898.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:187,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:179,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.86
-$0.86
Earnings Per Share Ttm:-$0.95

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.63

Book Value & Capital (2)

Book Value Per Share:-$1.05
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.7%
Fundamental Growth Rate (g):-26.0%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:BCLI
Company Name:BRAINSTORM CELL THERAPEUTICS INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:11.03M
Shares Outstanding Basic:11.03M
Shares Outstanding Diluted:11.03M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 16:14:43 UTC
Data Timestamp:2026-08-21T19:19:31.837547
Scroll to Top